Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000532939 | SCV000640747 | benign | Nemaline myopathy 2 | 2024-01-13 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003129899 | SCV003809579 | uncertain significance | not provided | 2023-11-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004639270 | SCV005146300 | uncertain significance | Inborn genetic diseases | 2024-06-11 | criteria provided, single submitter | clinical testing | The c.19329G>C (p.E6443D) alteration is located in exon 146 (coding exon 144) of the NEB gene. This alteration results from a G to C substitution at nucleotide position 19329, causing the glutamic acid (E) at amino acid position 6443 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000532939 | SCV002083946 | uncertain significance | Nemaline myopathy 2 | 2019-11-11 | no assertion criteria provided | clinical testing |